Nephron Pharmaceuticals, a major Midlands employer, faces mounting scrutiny over regulatory compliance, workplace conduct and leadership stability. A former human resources executive alleges the company falsified records during federal audits, failed to report missing fentanyl and retaliated against her for raising concerns. The allegations directly implicate CEO Lou Kennedy, who has since departed the company. The FDA cleared Nephron of a 2022 warning letter in May 2026 after the company addressed quality control issues, though questions persist about the company's operations and financial stability.
Read our previous coverage below.
Nola Grant, former chief human resources officer at Nephron, sued the company in June claiming she was subjected to discrimination based on race and disability, and that leadership retaliated against her after she reported corporate misconduct. Grant alleges CEO Lou Kennedy directed her to falsify applicant records during a federal audit, that the company provided altered surveillance footage to the FDA, and that it failed to report missing fentanyl to federal authorities. Grant also claims Kennedy subjected her to severe and pervasive racially discriminatory conduct, including hostile verbal...
Health care entities may be able to pay less than half the steep fines ordinarily associated with False Claims Act (FCA) violations by voluntarily reporting issues under a new pilot program launche...